View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 30, 2022

UC Davis MIND Institute to launch gene therapy programme for ADNP syndrome

The team will analyse three therapies, including a standard gene therapy, ASO, and a CRISPR-developed one, simultaneously.

Scientists at the UC Davis MIND Institute, in the US, are set to commence a research programme to develop transformative gene therapies for activity dependent neuroprotective protein (ADNP) syndrome.

The three-year, $4m programme is financed through a collaboration between the ADNP Kids Research Foundation, and Simba Global, a textile company. 

ADNP syndrome is a rare genetic ailment that causes delays in development and can impact parts of the body such as the brain, gastrointestinal system, and heart, among others.

It is caused by a mutation or variation in the ADNP gene that affects brain development, connectivity, and function. 

The impacts of the condition can be intense and may comprise speech delays, poor muscle tone, and sensory processing difficulties. 

The interventional genetics team of the institute, which involves specialists in mouse models for therapy development and in gene therapy, including the usage of the CRISPR gene-editing tool, will be part of the study.

This programme will have two major segments. 

In the initial phase, the team will leverage stem cell technology for developing a human ADNP model in Petri dishes. 

By assessing cognitive skills, sleep changes, and gait abnormalities, the researchers will also characterise mice with ADNP mutations.

The team will then perform a profound molecular characterisation of the mice cells.

The second portion of the research is to analyse treatments for ADNP. 

To expedite the development, the scientists will work on three separate therapies at the same time.

The treatments include a standard gene therapy, an antisense oligonucleotide (ASO), and a therapy being developed using the CRISPR tool.

Delivered using a virus, the standard gene therapy has obtained approval from the Food and Drug Administration (FDA) for spinal-muscular atrophy. 

The ASO attaches to the messenger ribonucleic acid (mRNA) for modulating gene expression. 

The therapies will be analysed in mice and the cells concurrently, allowing them to move forward rapidly.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper
img

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy

By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU